The artificial O2 carriers are used in the emergency condition where the need of the oxygen. There are many types here we can see the hemoglobin based carriers.
2. Presentation of Practice School
HEMOGLOBIN-BASED ARTIFICIAL
OXYGEN CARRIERS
Sejal Rakesh Pagar
Under the Guidance of
Mr. S. P. Jadhav
Divine Collage Of Pharmacy, Satana.
Academic Year: 2023-24
Date: 24/08/2023
3. CONTENT OF PRESENTATION
• INTRODUCTION
• Types of Artificial Oxygen Carriers:
• HB-BASED OXYGEN CARRIERS IN CURRENT USE AND
DEVELOPMENT
• ETHICAL ISSUES REGARDING HBOC CLINICAL
TRIALS
• LIMITATIONS OF BLOOD COMPONENT THERAPY
• ADVANTAGES
• DISADVANTAGES
• APPLICATIONS
• CONCLUSION
4. INTRODUCTION
• Hemoglobin-based oxygen carriers are artificial
substances designed to transport oxygen in the
bloodstream, potentially serving as blood substitutes
in medical treatments.
• Researchers since 1917 have sought oxygen-carrying
alternatives to red blood cells.
• They promise quick care in harsh environments,
potentially saving inaccessible treatment lives.
5. Types of Artificial Oxygen Carriers
1. Hemoglobin Based Artificial Oxygen
Carriers :
Hemoglobin taken directly from red blood
cells cannot serve as an intravascular
oxygen carrier due to its susceptibility to
spontaneous breakdown and potential
toxicity. Instead, HBOCs use purified
human, animal (bovines) or recombinant
hemoglobin as the starting materials. This
purified hemoglobin is then either
chemically modified or microencapsulated
2. Perfluorocarbons (PFCs):
Perfluorocarbons are fluorinated
hydrocarbon compounds that can
carry and deliver dissolved oxygen
under physiological conditions. To
be administered into the
intravascular space, they must be
biocompatible. Emulsification is
required for perfluorocarbons
because they do not readily mix
with aqueous systems like blood
6. Hb-BASED OXYGEN CARRIERS IN CURRENT
USE AND DEVELOPMENT
Hemopure:
• Developed by biopure
• Used in diverse contexts, with 32.5 g per 250 ml unit.
Oxyglobin:
• Approved for treating canine anemia.
Hemo2life:
• Derived from Arenicola Marina.
• Use in preservation,
• Potential use in transplantation
Oxyvita:
• Use in potential military applications, not yet used in human clinical trials.
9. ADVANTAGES
• It help transport oxygen in areas with limited blood access.
• It improves oxygen transport in low-oxygen situations.
• It simulate oxygen transport for lab experiments.
• It deliver oxygen during strokes/heart attacks, reducing tissue
damage.
• It assist in blood type and compatibility testing without real blood.
• It enhance organ viability during transplantation by providing
oxygen.
10. • Unstable oxygen release can harm tissues.
• Vasoconstriction raises blood pressure.
• Triggers inflammation and immune reactions.
• Lower oxygen capacity than red blood cells.
• Varying oxygen affinity leads to imbalances.
• Metabolic and renal effects, impacting kidneys.
• Regulatory challenges due to safety concerns.
• Ethical issues as potential blood substitutes.
DISADVANTAGES
11. 1. Emergency transfusions.
2. Ischemic conditions.
3. Critical care and anesthesia.
4. Remote medical care.
5. Organ preservation.
6. Blood substitutes for special cases.
7. Military and disasters.
8. High-altitude/deep-sea environments.
9. Lab research. Challenges limit approval.
APPLICATIONS
12. CONCLUSION
Hemoglobin-based oxygen carriers (HBOCS) are
promising alternatives to blood transfusions,
offering benefits like shelf life extension and
application in emergencies, anemia, and critical
care. However, they face challenges including renal
toxicity, vasoconstriction, and regulatory hurdles.
Ethical concerns arise from trials with waived
consent in life-threatening situations. Hbocs could
revolutionize healthcare, but ongoing research is
needed to overcome drawbacks and ensure safe
integration.
13. REFERENCE
1. Amberson wr, rhode cm, jennings jj. Clinical experience with hemoglobin-
saline solutions. Fed proc. 1946;5(1):2. Pmid: 21065870.
Https://pubmed.Ncbi.Nlm.Nih.Gov/21065870/
2. Savitsky JP, doczi J, black J, arnold JD. A clinical safety trial of stroma-free
hemoglobin. Clin pharmacol ther. 1978 jan;23(1):73-80. Doi: 10.1002/cpt197823173.
Pmid: 618711. Doi id : 10.1002/cpt197823173
3. Kim HW, greenburg AG. Artificial oxygen carriers as red blood cell
substitutes: a selected review and current status. Artif organs. 2004
sep;28(9):813-28. Doi: 10.1111/j.1525-1594.2004.07345.X. Pmid: 15320945. Doi id :
10.1111/j.1525-1594.2004.07345.X
4. Arnoldo BD, minei JP. Potential of hemoglobin-based oxygen carriers in
trauma patients. Curr opin crit care. 2001 dec;7(6):431-6. Doi: 10.1097/00075198-
200112000-00010. Pmid: 11805546. Doi: 10.1097/00075198-200112000-00010
